Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 23, 2026, the Company held a Special Meeting of Stockholders (the "Meeting"), which was convened virtually at www.virtualshareholdermeeting.com/PFSA2026, pursuant to notice duly given. Definitive proxy materials relating to the Meeting were filed with the Securities and Exchange Commission on May 26, 2026, and were transmitted to all stockholders that held of record as of May 12, 2026 (the "Record Date"). As of the close of business on the Record Date, there were 4,660,268 shares of the Company's common stock outstanding, each share being entitled to one vote. At the Meeting, the holders of 1,816,505 shares of the Company's common stock were represented in person or by proxy, constituting a quorum.

The stockholders voted to elect Lauren Chung as a Class I director, to hold office until the Company's 2029 annual meeting of stockholders and until her successor is duly elected and qualified, or until her earlier death, resignation or removal. The vote was as follows:

The stockholders were also asked to approve an amendment to the Company's Certificate of Incorporation, as amended, to, at the discretion of the Company's Board of Directors, effect one or more reverse stock splits over the course of the next two years of our common stock at a ratio of between 1-for-5 to 1-for-200, provided that the aggregate splits will not exceed a ratio of 1-for-200, including any shares held by the Company as treasury shares, at any time prior to or on June 23, 2028, with the exact ratio within such range to be determined at the discretion of our Board of Directors (or any of its delegated authorized persons) at its or their discretion without further approval or authorization of the Company's stockholders. The vote was as follows:

The stockholders were also asked to approve, for purposes of Nasdaq Listing Rules 5635(a) and 5635(d), the issuance by the Company of shares of a newly created series of convertible preferred stock (the "Preferred Stock") and the shares of common stock issuable upon conversion of the Preferred Stock to Bio Insights LLC as consideration for the Company's acquisition of certain assets relating to the PanOmics Assay pursuant to that certain Asset Purchase Agreement, dated as of April 21, 2026, by and between the Company and Bio Insights LLC. The vote was as follows:

The stockholders were also asked to approve, for purposes of complying with the applicable provisions of Nasdaq Listing Rule 5635(d), the potential issuance in excess of 19.99% of our outstanding shares of common stock upon the conversion of that certain promissory note issued by the Company to NorthView Sponsor I LLC, as modified pursuant to the Note Modification and Conversion Agreement, dated as of April 24, 2026, by and between the Company and NorthView Sponsor I LLC, as amended by Amendment No. 1 thereto, dated as of April 29, 2026. The vote was as follows:

The stockholders were also asked to approve an amendment to the Company's 2025 Equity and Incentive Plan (the "Plan") to increase the number of shares of the Company's common stock that are available to be issued pursuant to the Plan from 100,386 to 795,930 shares, an increase of 695,544 shares (such that the pool of shares available under the Plan will represent 15% of the Company's outstanding shares of common stock, calculated based on 4,510,268 shares of common stock outstanding as of May 7, 2026) (after giving effect to the reverse stock split). The vote was as follows:

The stockholders were also asked to authorize an adjournment or adjournments of the Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are not sufficient votes in favor of the first two proposals. The vote was as follows:

No other actions were taken at the meeting.